ANGO vs RGNX
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
ANGO shows bearish fundamentals based on deterministic rules. Financial strength is weak (F-Score 1/9). Concerns include weak profitability or high valuation.
RGNX exhibits significant financial fragility, evidenced by a weak Piotroski F-Score of 3/9 and a lack of deterministic value markers like the Graham Number. While the company shows strong top-line revenue growth of 43%, this is offset by severe profitability deficits, including a profit margin of -113.75% and consistent earnings misses over the last four quarters. The stark divergence between the current price ($9.49) and the analyst target ($27.82) suggests a speculative valuation based on future pipeline success rather than current fundamentals. High debt-to-equity (2.54) and bearish insider sentiment further compound the risk profile.
Compare Another Pair
Related Comparisons
ANGO vs RGNX: Head-to-Head Comparison
This page compares AngioDynamics, Inc. (ANGO) and REGENXBIO Inc. (RGNX) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.